Hepatitis C is a liver infection caused by the hepatitis C virus. Hepatitis C can range from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C is often described as “acute,” meaning a new infection or “chronic,” meaning lifelong infection. The virus is most commonly spread through sharing needles syringes, or other equipment used to inject drugs; accidental needle-sticks in healthcare settings; and being born to a mother who is already infected. VA research into hepatitis C addresses prevention, treatment, and managing quality of life.
Search results were generated based on the search term "Hepatitis C". Results are updated weekly, as new data are available.
VIEW: Citations | Publication Briefs | Studies | HSR&D Briefs, Reports, Newsletters | Topic Spotlight | Cyberseminars | Videos | Podcasts | Other Resources
(5 of more than 419 HEPATITIS C focused publications)
- Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World journal of hepatology. 2020 Sep 27; 12(9):628-640.
- Vutien P, Kim NJ, Moon AM, Pearson M, Su F, Berry K, Gelman H, Ioannou GN. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. Alimentary pharmacology & therapeutics. 2020 Dec 1; 52(11-12):1717-1727.
- Yakovchenko V, DeSotto K, Drainoni ML, Lukesh W, Miller DR, Park A, Shao Q, Thornton DJ, Gifford AL. Using Lean-Facilitation to Improve Quality of Hepatitis C Testing in Primary Care. Journal of general internal medicine. 2020 Sep 15.
- Beste LA, Green P, Berry K, Belperio P, Ioannou GN. Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. JAMA. 2020 Sep 8; 324(10):1003-1005.
- Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, Tapper EB, Singal AG, Zhu J, Waljee AK. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Network Open. 2020 Sep 1; 3(9):e2015626.
» View more Citations
(5 of more than 18 HEPATITIS C focused publication briefs)
- Veterans Advocate Treating “Sickest First” When Discussing Limited Resources for Hepatitis C Treatment
Investigators in this study used Democratic Deliberation (DD) methods as a proof of concept for informing policy decisions related to the allocation of scarce resources for treatment of chronic hepatitis C virus in VA. Findings showed that most Veterans endorsed a sickest-first policy over a first-come-first-served policy, emphasizing the ethical and medical appropriateness of treating the sickest...
Date: May 1, 2020
- VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
Date: March 7, 2018
- HCV-Related Complications Increasing among Women Veterans
This study examined gender-related differences in the incidence and prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular cancer (HCC) between 2000 and 2013. Findings showed that the incidence and prevalence of hepatitis C virus (HCV) complications was higher in men than in women. However, the rate of increase in the incidence rates of cirrhosis and decompensated cirrhosis among HCV...
Date: November 1, 2017
- Direct-Acting Antiviral Agents Reduce Risk of Hepatocellular Cancer among Veterans with Hepatitis C
This study examined the risk of hepatocellular cancer (HCC) following sustained virological response (SVR) among 22,500 Veterans with hepatitis C virus (HCV) who received directing-acting antivirals (DAA) treatment at any of 129 VA hospitals between January and December 2015. Findings showed that in Veterans treated with DAAs, SVR was associated with a 76% reduction in the risk of developing hepat...
Date: October 1, 2017
- VA Hepatitis C Care and Experiences with the Choice Program
This study examined perspectives and experiences with the VA Choice Program among Veterans with HCV and their providers at three VAMCs in the New England region. Findings showed that the Choice Program has the potential to increase Veterans’ access to hepatitis C virus (HCV) treatment, but Veterans and VA providers described substantial problems in the initial years of the program. Four main theme...
Date: March 3, 2017
» View more Publication Briefs
( 5 of more than 27 HEPATITIS C focused projects
|| Advanced Prediction Models to Optimize Treatment and Access for Veterans with Hepatitis C
|| Quality of Care for Hepatitis C in Veterans Who Are Homeless
|| Care for Women Veterans with Hepatitis C Virus Infection
|| Web-based Intervention to Reduce Alcohol Use in Veterans with Hepatitis C
|| Cost-effective Uses of New Hepatitis C Treatments and their VA Budgetary Impact
» View more Studies
There are currently no spotlight features on this topic.
The most recent "Hepatitis C" seminars are displayed.
Measuring Implementation Strategies to Inform Hepatitis C Quality Improvement: Lessons from the Field
|| Rogal, Shari
Implementation Strategies and the Uptake of Hepatitis C Treatment in VA
|| Rogal, Shari
Focus on Health Equity and Action: Treatment of HCV- ALD Among VHA Vulnerable Populations
|| Julie, Lynch
Focus on Equity and Action—Office of Health Equity Hepatitis C Virus-Advanced Liver Disease Disparities Dashboard
|| Uchendu, Uchenna
Hepatitis C Self-Management Program
|| Weingart, Kimberly
» View more Cyberseminars
There are currently no videos for this topic.
There are currently no podcasts for this topic.